

Stallkamp, Jennifer

From: Adam Chesler <adam@realsolutionsgroup.co>
Sent: Monday, December 2, 2024 4:49 PM
To: Bough, Marcie <MBough@mt.gov>
Subject: [EXTERNAL] Request to discuss pharmacy topic

Marcie-

Hope you had a good thanksgiving!

I am reaching out regarding tirzepatide being removed from the drug shortage list. Since FDA's announcement, there has been an increase in compounding activity that circumvents FDA shortage requirements, including the marketing of oral formulations that lack efficacy (due to very low bioavailability), encouraging patients to stockpile tirzepatide, and introducing new injectable formulations that contain vitamin additives.

We have been monitoring this activity and have identified several companies that are marketing and supplying illegally compounded tirzepatide to Montana patients. Our client Eli Lilly intends to send a letter to the Montana Board of Pharmacy outlining these concerns. After you receive the letter, Eli Lilly would greatly appreciate the opportunity to meet with the Board staff and discuss the best way such information can be shared with the Board moving forward.

Happy to jump on a call to explain further (512-694-8556)

Thanks,
Adam Chesler, PharmD

The information provided in this email does not, and is not intended to, constitute legal advice; instead, all information, content, and materials contained within this message are for educational and/or consultative purposes only.